Losatan

Quick links to important sections

Losatan

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Losatan

Quick Facts: Losartan

Property Description
Active ingredient Losartan potassium
Form Oral tablets
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Lowering high blood pressure
Origin Synthetic compound

What Type of Medicine is Losartan (Losatan)?

Losartan is a prescription-only, synthetic medicine categorized primarily as an Angiotensin II Receptor Blocker (ARB), often referenced in clinical settings as an Angiotensin Receptor Antagonist. This pharmacological class is distinguished by its mechanism of blocking the receptor sites for the potent vasoconstrictor hormone, Angiotensin II. Unlike older classes of antihypertensives, the specific mechanism of ARBs is recognized for providing a significant benefit in managing sustained high blood pressure, and it is a standard-of-care agent for this condition. The specific INN, Losartan, is sold under various trade names, including Cozaar and its generic equivalents, and is recognized as an essential component of modern cardiovascular management.


Composition and Form: Understanding Losartan Potassium

The active component in this medication is Losartan potassium, which is the standardized International Non-proprietary Name (INN) for the drug substance. Losartan is administered in the form of an oral tablet for systemic absorption, and it utilizes solid pharmaceutical excipients as its base vehicle. The medicine is available both as a single-entity product containing only Losartan potassium, and in combination tablets that include a diuretic, such as hydrochlorothiazide, to offer a dual approach to blood pressure management.


General Purpose: What Does Losartan Help to Achieve?

The core therapeutic goal of Losartan is to effectively lower high blood pressure by facilitating the relaxation of blood vessels. Losartan achieves this by blocking the action of Angiotensin II, which normally causes blood vessels to constrict. This action promotes the relaxation and widening (vasodilation) of blood vessels, thereby reducing the total peripheral resistance to blood flow. This general mechanism reduces the total peripheral resistance and lessens the workload on the heart, ultimately contributing to overall improved circulatory health and mitigating the long-term risk associated with chronic hypertension.

What side effects are possible with Losatan?

Possible Side Effects and Safety Information

The official safety profile for Losartan potassium, an Angiotensin II Receptor Blocker, classifies potential adverse reactions by frequency and physiological system as defined in regulatory documents.

Frequency-Classified Adverse Reactions

Adverse effects are grouped into frequency categories based on their observed incidence:

  • Common (may affect up to 1 in 10 people): Reactions frequently documented in official labeling include dizziness, vertigo, upper respiratory infection, nasal congestion, and back pain. Changes in kidney function and low blood pressure (hypotension) are also classified as common in specific patient groups.
  • Uncommon (may affect up to 1 in 100 people): Documented effects include headache, somnolence (drowsiness), rash, diarrhoea, nausea, and cough.
  • Rare (may affect up to 1 in 1,000 people): Serious hypersensitivity reactions such as Angioedema (swelling of the face, lips, or throat), Hepatitis, and Cerebrovascular Accident (stroke) have been reported.

Serious Safety Constraints and Population-Specific Risks

The most critical safety constraint is the official Boxed Warning for Fetal Toxicity. Use during pregnancy can cause injury and death to the developing fetus, and the medicine must be discontinued immediately if pregnancy is detected.

The label also documents risks for Hyperkalemia (high blood potassium) and potential for changes in renal function, particularly in susceptible patients. Higher drug concentrations are noted in individuals with hepatic impairment, which requires specific consideration.

Regarding time-related patterns, symptoms like dizziness and low blood pressure are noted to be more common when first starting treatment or following an increase in dose.

Overdose and Emergency Response

Losartan Overdose and When to Seek Help

Losartan overdose is primarily documented in regulatory prescribing information as manifesting through significant cardiovascular effects. The most common clinical signs include a notable drop in blood pressure, known as hypotension, which may be severe. Changes in heart rhythm are also reported, presenting either as an abnormally increased heartbeat (tachycardia) or, less commonly, a decreased heartbeat (bradycardia), potentially due to vagal stimulation.

Required Emergency Action

If an individual has taken too much Losartan potassium tablets, regulatory guidance explicitly mandates seeking immediate medical attention. This official action involves contacting a Poison Control Center or proceeding to the nearest hospital emergency room right away due to the potential for severe symptomatic hypotension.

Management and Special Considerations

Management of an overdose relies entirely on symptomatic and supportive treatment to address the presenting manifestations, as no specific antidote is listed in the official labeling.

Regulatory documents note specific considerations for neonates exposed to Losartan in utero. These infants must be closely monitored for severe effects, including hypotension, decreased urine output (oliguria), and high blood potassium (hyperkalemia). In these severe instances, advanced medical procedures such as exchange transfusions or dialysis may be required as part of the management protocol to support their blood pressure and renal function.

Therapeutic Uses of Losatan

Quick Facts

  • May help manage high blood pressure (hypertension).
  • May help reduce the risk of stroke in certain patients with high blood pressure and an enlarged heart (left ventricular hypertrophy).
  • Used to address kidney complications in patients who have type 2 diabetes and high blood pressure.

Losatan is a prescription medication utilized in therapeutic regimens for several cardiovascular and renal conditions. Its primary function is to help manage sustained high blood pressure, or hypertension. Maintaining blood pressure within an acceptable range is a key strategy to support overall cardiovascular well-being.

In individuals diagnosed with both hypertension and left ventricular hypertrophy (an enlarged heart), Losatan is used to potentially reduce the risk of experiencing a stroke. Additionally, the drug is used in the care plan for patients with type 2 diabetes who have developed kidney issues, also known as diabetic nephropathy, where it may help address the progression of the condition.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Losartan

Official regulatory guidelines define specific patient populations for whom the use of Losartan is permitted, restricted, or absolutely contraindicated.

Absolute Contraindications

Losartan is contraindicated and must not be used by patients with a known hypersensitivity to the drug or any of its components. It is also strictly contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm; use must be discontinued immediately if pregnancy is detected. A key comorbidity exclusion applies: Losartan is contraindicated in patients with diabetes mellitus who are concurrently receiving any medication containing aliskiren.

Population Eligibility and Restrictions

Use is established for adults across all licensed indications. For pediatric patients, Losartan is approved only for the treatment of hypertension in children and adolescents aged 6 to 16 years. Use is not recommended for children under 6 or in pediatric patients with severe renal impairment (eGFR <30 mL/min/1.73 m^2). For patients with severe hepatic impairment, Losartan is not recommended as its safety has not been established in this group. Use is also not recommended for women who are breastfeeding. Patients with pre-existing volume or salt depletion must have this condition corrected before starting treatment.

What should I know about interactions with other medicines?

Losartan Interactions with Other Medicines and Products

This section outlines interactions with Losartan potassium based solely on official regulatory findings.


Formally Documented Contraindicated Combinations

Co-administration of Aliskiren is contraindicated in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate less than 60 mL/min/1.73 m²). The dual blockade of the Renin-Angiotensin System (RAS) by Losartan and an ACE Inhibitor is generally avoided due to increased risks of severe hypotension, hyperkalemia, and kidney function changes.


Pharmacodynamic and Exposure Interactions

Interacting Substance/Class Official Interaction Statement
Agents Increasing Serum Potassium (e.g., Potassium-sparing diuretics, supplements) May increase the risk of hyperkalemia (high potassium in the blood).
Lithium May lead to an increase in serum lithium concentrations and the risk of toxicity.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) May reduce the blood pressure-lowering effect of Losartan and increase the risk of kidney function deterioration.
Fluconazole (CYP2C9 Inhibitor) Documented to increase Losartan exposure and decrease the active metabolite’s exposure.
Rifampin (CYP Inducer) Documented to decrease Losartan exposure and the active metabolite’s exposure.

Other Regulatory Interaction Notes

Interactions leading to significantly increased Losartan exposure are formally noted in patients with hepatic impairment (liver dysfunction) and renal impairment. Regarding products, potassium supplements and salt substitutes containing potassium are explicitly listed as having a heightened risk of interaction (hyperkalemia).

Mechanism of Action

Losartan is a selective, competitive antagonist of the Angiotensin II type 1 ( AT1) receptor. It blocks the binding of the potent vasoconstrictor, Angiotensin II, to the AT1 receptors located on vascular smooth muscle, cardiac tissue, renal tissue, and the adrenal glands. This blockade interrupts the core signaling within the Renin-Angiotensin-Aldosterone System ( RAAS). In the vasculature, interruption of AT1 signaling causes vasodilation, which decreases peripheral resistance. In the adrenal glands, the blockade suppresses the Angiotensin II-mediated release of aldosterone. Reduced aldosterone leads to decreased reabsorption of sodium and water by the renal tubules, resulting in natriuresis and a subsequent reduction in circulating blood volume. Furthermore, Losartan's action limits the trophic (growth-promoting) effects of Angiotensin II on the heart and kidneys, thereby reducing AT1-mediated cell hypertrophy and fibrosis.

Dosage and Administration Information

Losartan is an oral medication administered as a tablet or a specially compounded liquid suspension. The medicine is consistently prescribed as a once-daily regimen for all labeled uses, which supports a continuous therapeutic effect.

Standard Dosing and Administration

The standard starting dose for adult hypertension is 50 mg once daily. The maximum daily dose for Losartan in adults is 100 mg. The administration may occur with or without food, providing flexibility for daily intake. The full blood pressure-lowering effect is typically achieved over a period of three to six weeks, which guides the timeline for any dose adjustment, or titration, to the higher 100 mg dose.

Population-Specific Usage

Losartan use requires adjustment for certain patient populations. A lower starting dose of 25 mg once daily is designated for patients with either mild-to-moderate hepatic impairment or those who are considered volume-depleted (e.g., currently receiving high-dose diuretic therapy). For children aged six years and older with hypertension, the dose is determined based on weight, starting at 0.7 mg/kg once daily and not to exceed the 100 mg total daily maximum.

Missed Dose Protocol

If the administration schedule is missed, standard protocol specifies that the user should skip the missed dose if it is near the time for the next scheduled dose. The protocol strictly directs that the dose should not be doubled to compensate for the skipped one.

Recent Clinical Evidence

Research evidence / Overview of Studies for Losatan

Evidence for Use in Managing High Blood Pressure (Essential Hypertension)

Research on losartan, concerning high blood pressure, has primarily relied on Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies were used to examine changes in systolic and diastolic blood pressure (BP) measurements, which are key outcomes reflecting physiological strain. Researchers also looked at the patterns observed in the long-term incidence of cardiovascular outcomes studied, which included stroke and myocardial infarction. The populations studied included a wide range of adults with essential hypertension, and the findings describe changes in blood pressure levels across these groups. It remains uncertain how the long-term cardiovascular outcomes observed in losartan trials align with those observed in trials of all other contemporary antihypertensive medications, as the most definitive long-term trials often contrasted losartan with a placebo or with certain older comparator drugs.


Evidence for Reducing Stroke Risk in Patients with High Blood Pressure and LVH

A substantial, dedicated Randomized Controlled Trial (RCT) was conducted to explore patterns in the occurrence of stroke in adult patients who had both hypertension and Left Ventricular Hypertrophy (LVH), a condition referring to an enlarged heart. This research specifically examined the pattern of occurrence for fatal and nonfatal stroke as a primary outcome. Studies monitored the rates of stroke events in the losartan group and compared them to the comparator group over an observation period of around four to five years. It is noted in regulatory documents that the specific findings regarding stroke patterns did not apply to the subgroup of Black patients included in that primary trial.


Evidence for Addressing Kidney Complications in Type 2 Diabetes

The evidence related to losartan and kidney issues in patients with Type 2 Diabetes who have developed nephropathy comes from specific, long-term Randomized Controlled Trials (RCTs). These studies were designed to monitor outcomes related to systemic or functional imbalance over several years in adult patients with both hypertension and evidence of kidney damage. The research used a combined primary outcome to measure the time until a patient experienced events, including the progression to End-Stage Renal Disease (ESRD), as measured in the study. Findings monitored the progression rate of the composite renal endpoint between the losartan-studied group and the control group over the intermediate term. Importantly, the initial large trials generally excluded patients with Type 1 Diabetes, and data on all-cause mortality was mixed or less consistent across different study analyses.


Key Evidence Gaps and Areas of Research Uncertainty

The research base, while robust for the primary indications, contains several limitations. Comparative evidence is lacking when attempting to judge the full cardiovascular outcomes of losartan directly against all available modern blood pressure medications. Additionally, the results apply only to the populations studied, meaning the applicability of specific findings to patients with unique or complex medical histories not represented in the trials may be uncertain. Finally, while short-term data exists for pediatric hypertension, the long-term effects are not fully established for cardiovascular event prevention in children and adolescents.

Key Studies & References

  1. Losartan for the treatment of hypertension in children and adolescents

Frequently Asked Questions (FAQ)

Common questions about Losatan (FAQ)

Q: Is Losatan a diuretic?

A: Losatan is classified as an Angiotensin II Receptor Blocker (ARB), not a diuretic (or 'water pill'). However, its mechanism of action results in an effect on the body's salt and water balance, which can lead to increased excretion of water and salt.

Q: Is Losatan the same as 'water pills'?

A: Losatan is an Angiotensin II Receptor Blocker (ARB), which is a different class of medicine than diuretics, commonly called 'water pills.' Official product information identifies it as a separate pharmacological class. Losatan is sometimes prescribed in a combination pill that includes a diuretic.

Q: Does Losatan affect electrolyte levels?

A: Yes, official regulatory documents note that Losatan may cause an increase in serum potassium levels in the blood, a condition called hyperkalemia. This occurs because the medicine can influence the release of a hormone that normally manages the body’s potassium and sodium balance.

Q: How long does Losatan stay in your system?

A: Pharmacokinetic data indicates that the medicine and its active component are eliminated from the body over time. The terminal half-life of the active component is about six to nine hours, and its half-life supports its use as a once-daily medication, as described in regulatory documents.

Q: What is the evidence that Losatan helps with heart failure?

A: The core evidence for Losatan relates to high blood pressure, reducing stroke risk in patients with LVH, and kidney complications in Type 2 Diabetes. By reducing the heart’s workload, this action may contribute to improved circulatory health over time.

Q: What should I do if I experience a persistent side effect with Losatan?

A: Official patient information consistently directs that users should contact their healthcare provider if any side effects are persistent, worsen, or cause concern. Emergency symptoms, such as sudden swelling of the face, tongue, or throat (Angioedema), are described in patient information as requiring immediate emergency medical assistance.

Q: Can Losatan cause swelling in the legs or ankles?

A: The official safety profile documents swelling of the lips, face, throat, and tongue (Angioedema) as a rare, serious hypersensitivity reaction. Swelling in the legs or ankles (peripheral edema) is not listed as a common or uncommon side effect in the official frequency tables for Losatan.

Q: Does Losatan change how fast your heart beats?

A: Losatan's primary action is to lessen the heart's workload and reduce resistance in the blood vessels. While some studies have observed a change in heart rate in patients with certain conditions like heart failure, other studies in patients with high blood pressure have noted that heart rate remained unchanged.

Q: Why is potassium intake mentioned in relation to Losatan?

A: The official product information mentions potassium intake because Losatan’s mechanism of action can lead to increased serum potassium levels (hyperkalemia). Because of this risk, regulatory documents explicitly warn against combining Losatan with potassium supplements or salt substitutes containing potassium.

Q: Can Losatan be crushed or split?

A: The tablet form, such as the 50 mg strength, is often manufactured with a score line, which suggests it is designed to be split. Official patient information advises following the specific instructions from the prescribing healthcare provider or pharmacist regarding the preparation and administration of the medicine.

Q: Does Losatan interact with common pain relievers like ibuprofen?

A: Yes, Losatan is documented to interact with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen. The official warning indicates this combination may lessen Losatan's blood pressure-lowering effect and may also increase the risk of changes in kidney function, particularly in elderly or volume-depleted individuals.

Q: Are there any common foods to avoid while taking Losatan?

A: The primary restriction noted in regulatory documents relates to potassium-containing salt substitutes due to the heightened risk of developing high potassium levels (hyperkalemia). Losatan can be taken with or without food.

Q: What are the long-term effects of taking Losatan?

A: Long-term studies have examined the patterns of occurrence for major cardiovascular outcomes and the progression of kidney disease in specific populations. The goal of continuous therapy is to maintain reduced blood pressure to help manage the associated long-term health risks.

Q: Can Losatan affect sleep?

A: Yes, the official safety profile for Losatan lists insomnia (difficulty sleeping) as a reported side effect. Additionally, somnolence (drowsiness or an urge to sleep) is documented as an uncommon adverse effect.

Q: Is Losatan the same as the drug Valsartan?

A: Losatan and Valsartan are both Angiotensin II Receptor Blockers (ARBs) that share the same pharmacological class and core mechanism of action. However, regulatory agencies have granted approvals for slightly different labeled uses and dosing requirements for each specific medicine.

Q: Does Losatan require regular blood tests?

A: Yes. Due to the potential for Losatan to affect kidney function and its potential to increase blood potassium levels, official patient information advises having blood work checked regularly, as instructed by the prescriber.

Q: Is Losatan a 'statin' medicine?

A: No. Losatan is classified as an Angiotensin II Receptor Blocker (ARB), a type of medicine used to lower high blood pressure. Statins are a different pharmacological class of medicine used to manage cholesterol levels.

Q: Does Losatan affect cholesterol levels?

A: Losatan's primary approved purpose is the control of high blood pressure and related conditions. It is not indicated as a primary treatment for affecting cholesterol levels, though its use is often combined with cholesterol-lowering medicines (statins).

Q: What is the risk of Losatan causing low blood pressure (hypotension)?

A: Low blood pressure (hypotension) is listed in the safety profile as a common adverse reaction. Official documents describe that symptomatic hypotension may occur in patients who are intravascularly volume-depleted, meaning they have a low volume of fluid in their blood vessels.

Q: Is it possible to be allergic to the inactive ingredients in Losatan?

A: Yes. Official contraindications state that Losatan must not be used by patients who have a known hypersensitivity to the drug's active ingredient or any of its components. This warning includes the inactive ingredients, or excipients, used to form the tablet.

Q: What are the common reasons someone might stop taking Losatan?

A: Official safety information notes that discontinuation has occurred due to the detection of pregnancy or intolerance of side effects, such as a serious reaction like Angioedema (swelling). Discontinuation also occurs when treatment is deemed no longer necessary.

Q: Does Losatan have any known interactions with herbal supplements?

A: The official interaction list explicitly includes a warning for potassium supplements and salt substitutes that contain potassium, which may be found in some herbal products. Regulatory bodies advise caution regarding other herbal remedies as they are not tested with the drug in the same way as prescription medicines.

Q: Are there restrictions on driving while taking Losatan?

A: Official patient information advises users to avoid driving or performing tasks that require alertness until they are aware of how the medicine affects them. This caution is based on documented side effects like dizziness and somnolence (drowsiness).

Q: How does Losatan compare to an ACE inhibitor in official descriptions?

A: Losatan is an Angiotensin II Receptor Blocker (ARB), which works by selectively blocking the AT1 receptor. ACE inhibitors block the formation of Angiotensin II, a different step in the same system. Official information indicates Losatan's mechanism of action is associated with a lower risk of the persistent, dry cough linked to ACE Inhibitors.

Q: What is the research history of Losatan?

A: The active compound Losatan was patented in the early 1990s and received its initial approval from the U.S. Food and Drug Administration (FDA) in 1995. The drug's history includes major clinical trials that established its use in specific patient populations, such as those with high blood pressure and left ventricular hypertrophy.

Q: Do children ever take Losatan?

A: Yes. Losatan is approved for the treatment of high blood pressure in children and adolescents who are six years of age and older. Use is not recommended for children under six or in pediatric patients who have severe kidney function changes.

Q: Does Losatan interact with alcohol?

A: Yes. The official information notes that consuming alcohol may enhance the blood pressure-lowering effect of Losatan. This combination can lead to increased feelings of dizziness or light-headedness.

Q: Can Losatan be taken at night instead of in the morning?

A: The official dosing is described as a once-daily administration. Regulatory documents do not specify a time of day, offering flexibility for the user. Losatan can be taken with or without food.

Q: What are the common reasons for a doctor to switch a patient to Losatan?

A: Official information indicates Losatan's mechanism of action is associated with a lower risk of the persistent, dry cough often linked to ACE inhibitors, suggesting a clinical reason for its use as an alternative.

Q: Does Losatan have different effects on men and women?

A: Official clinical trial analyses have examined the treatment effects in both male and female patients. These analyses have indicated that the benefit for key outcomes, such as stroke reduction in patients with high blood pressure and an enlarged heart, was generally consistent in both men and women.

Q: Is it a common issue to have muscle cramps while on Losatan?

A: Yes, official safety documents list muscle pain or cramps as a documented adverse event associated with Losatan use. The frequency is categorized as common (may affect up to 1 in 10 people) when Losatan is used in combination with a diuretic.

Q: Are there official warnings about combining Losatan with other antihypertensives?

A: Yes. Regulatory documents carry specific warnings against the dual blockade of the Renin-Angiotensin System (RAS). Combining Losatan with an ACE inhibitor or Aliskiren is generally avoided due to increased risks of severe low blood pressure, high potassium, and changes in kidney function.

How should Losatan be stored and disposed of?

Losartan potassium tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from excessive heat, moisture, and light. Keep the medication in the container it came in, with the container tightly closed.

A compounded Losartan oral suspension, however, requires refrigeration (2 C to 8 C) and is stable for a limited time, such as up to 60 days after opening, as per some regulatory labeling. Tablets should not be frozen.

For disposal of unused or expired Losartan, the official recommendation is to use a drug take-back program. As Losartan is not on the official flush list, it should not be flushed down the toilet. If a take-back program is unavailable, mix the tablets with an undesirable substance (e.g., dirt) in a sealed bag and discard in the household trash. The medication must always be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Losatan found in:

A-Z Index: